<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144289">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222299</url>
  </required_header>
  <id_info>
    <org_study_id>S00032</org_study_id>
    <nct_id>NCT01222299</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bepotastine Besilate Nasal Product in Seasonal Allergic Rhinitis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of bepotastine besilate
      nasal product in seasonal allergic rhinitis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Pharmacokinetics(PK)of bepotastine besilate nasal spray vs. placebo</measure>
    <time_frame>5 weeks after 1st dose (FPFV-LPLV)</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bepotastine besilate nasal product - low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bepotastine besilate nasal product - medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bepotastine besilate nasal product - high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator nasal product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bepotastine besilate nasal product - low dose</intervention_name>
    <description>sterile nasal product</description>
    <arm_group_label>Arm 1 - Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bepotastine besilate nasal product - medium dose</intervention_name>
    <description>sterile nasal product</description>
    <arm_group_label>Arm 2 - Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bepotastine besilate nasal product - high dose</intervention_name>
    <description>sterile nasal product</description>
    <arm_group_label>Arm 3 - High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo comparator nasal product</intervention_name>
    <description>sterile nasal product</description>
    <arm_group_label>Arm 4 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 18 to 65 years of age with a positive skin prick test to allergen

        Exclusion Criteria:

          -  No active respiratory tract infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim McNamara, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>ISTA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISTA Pharmaceuticals, Inc.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>October 14, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>September 2, 2011</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
